...
【24h】

A new radioligand binding assay to measure the concentration of drugs in rodent brain ex vivo

机译:一种新的放射性配体结合测定法,用于体外测量啮齿动物脑中药物的浓度

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We have developed a new radioligand binding assay method to measure the concentration of nonradiolabeled drugs in the brain ex vivo. This new method fuses the concepts of standard competition and saturation binding assays and uses a transformed version of the Cheng-Prusoff equation (Biochem Pharmacol 22:3099-3108, 1973) to calculate the drug concentration. After testing the validity of this method, we demonstrated its utility by measuring the brain concentration of sazetidine-A, a newly developed nicotinic receptor ligand, and its elimination rate after a single subcutaneous administration. Our results indicate that sazetidine-A reaches brain concentrations that are known to occupy and desensitize the majority of neuronal nicotinic acetylcholine receptor binding sites. Furthermore, using this method, we estimated the half-life of sazetidine-A in the rat brain to be ~65 min. It is important to note that the method described here to measure sazetidine-A in brain should be generalizable to other drugs acting at any receptor that can be reliably measured with a radiolabeled ligand.
机译:我们已经开发出一种新的放射性配体结合测定方法,以测量离体大脑中非放射性标记药物的浓度。这种新方法融合了标准竞争和饱和结合测定的概念,并使用了Cheng-Prusoff方程的转换版本(Biochem Pharmacol 22:3099-3108,1973)来计算药物浓度。在测试此方法的有效性之后,我们通过测量新开发的烟碱样受体配体sazetidine-A的大脑浓度及其单次皮下给药后的消除率来证明其实用性。我们的结果表明,sazetidine-A达到已知占据和使大多数神经元烟碱型乙酰胆碱受体结合位点脱敏的大脑浓度。此外,使用这种方法,我们估算了sazetidine-A在大鼠脑中的半衰期约为65分钟。重要的是要注意,此处描述的测量脑中sazetidine-A的方法应可推广到作用于任何受体的其他药物,这些药物可以用放射性标记的配体可靠地进行测量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号